2. Search Result
Search Result
Results for "

RSL3-4-Me

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153368
    Zomiradomide

    KT-413

    		 IRAK PROTACs Cancer
    KT-413 (example I-3) is an orally active PROTAC-class IRAK degrader . KT-413 consists of a target protein ligand (red part) PROTAC IRAK4 ligand-5 (HY-168311), an E3 ubiquitin ligase ligand (blue part) Thalidomide-4-Br (HY-W039116), and a PROTAC linker (black part) 2-(2-Azaspiro[3.3]heptan-6-yl)ethanamine (HY-168313). E3 ubiquitin ligase and linker can form Thalidomide-NH-C2-2-azaspiro[3.3]heptane (HY-168312). The active control for the target protein ligand is RSL3-4-Me (HY-169375).
    Zomiradomide
  • HY-169375
    RSL3-4-Me

    		Ligands for Target Protein for PROTAC Cancer
    RSL3-4-Me is a Ligand for Target Protein for PROTAC activity control. RSL3-4-Me can be used to synthesize NC-R17 (HY-155075) .
    RSL3-4-Me
  • HY-155075
    NC-R17

    		PROTACs Glutathione Peroxidase Ferroptosis Cancer
    NC-R17 is a PROTAC-class, non-covalent GPX4 degrader based on RSL3, involved in ferroptosis. NC-R17 has antitumor activity and is used for non-covalent GPX4 PROTAC design . NC-R17 consists of a target protein ligand (red part) Demethyl-RSL3 (HY-135832); an E3 ubiquitin ligase ligand (blue part) Lenalidomide (HY-A0003) and a PROTAC linker (black part) (HY-169376). E3 ubiquitin ligase and linker can form Lenalidomide-C13-piperazine-Boc (HY-169377); the active control for the target protein ligand is RSL3-4-Me (HY-169375).
    NC-R17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: